November 27, 2025
Giving Tuesday is December 2. Help us break down barriers to life-saving treatment on this global day of generosity.
Canadians living with myeloma are facing a setback in their ability to receive life-saving treatment. This Giving Tuesday, Myeloma Canada and Andrew Gray, a member of our community who lives with myeloma, are appealing to you to support the fight for Canadians’ rights to the treatments they need to live. Giving Tuesday is a global movement that celebrates generosity and encourages people to take collective action for good. Your support can make a real difference.
The fundraising goal for this year’s 2025 Giving Tuesday campaign is $25,000 to strengthen our work for every Canadian’s right to the life-changing treatments they are currently being denied.
Every donation helps us push back against the barriers that prevent Canadians from receiving the care they need to live.
[Photo: Andrew Gray and his wife Nancy Gray]
“Imagine how shocked [my wife] and I were when we found out that Carvykti®, a very effective and promising new CAR T-cell therapy will not be available to Canadians with myeloma, even though it was approved by Health Canada in 2023! The reason? Reimbursement and price negotiations were terminated without reaching an agreement. Bureaucracy is literally playing with our lives,” says Andrew Gray in this month’s Spotlight article.
Help us reach our $25,000 goal this Giving Tuesday. Your gift fuels the fight for access to life-saving treatments.
More about the recent setback
Canadians were recently denied access to Carvykti® after pricing negotiations fell through, leaving patients without a critical treatment option. Carvykti® is a CAR T-cell therapy, a treatment that uses a patient’s own immune cells to fight cancer. It offers hope to Canadians with myeloma, especially those who have exhausted other options. Although it was approved for use by Health Canada in 2023, pricing negotiations to make the treatment available to Canadians with myeloma fell through this Fall, blocking access to this potentially life-saving treatment.